IMB-102 is a monoclonal antibody with an OX40L binding site, primarily functioning through adaptive immune modulation. It is currently undergoing indication exploration studies.

OX40L is a key regulator of the immune system, possessing the ability to bidirectionally activate and induce the differentiation of T cells and antigen-presenting cells. It also contributes to the production of autoantibodies, playing a significant pathogenic role in autoimmune diseases. By blocking OX40L, IMB-102 can help achieve immune equilibrium, providing therapeutic benefits for various autoimmune diseases.

By blocking OX40L, superior therapeutic effects compared to competing drugs have been confirmed in in vitro and ex vivo studies.